（文章来源：每日经济新闻） 每经AI快讯，歌礼制药-B(01672.HK)涨超4%，截至发稿涨4.25%，报14.23港元，成交额2682.71万港 元。 ...

Core Viewpoint - The stock of Gilead Sciences-B (01672) has risen over 4%, currently trading at 14.23 HKD, with a transaction volume of 26.83 million HKD, following the acceptance of its new drug application for Denifanstat by the CDE [1] Company Developments - Gilead's new drug Denifanstat (ASC40) is a potential first-in-class oral fatty acid synthase (FASN) inhibitor, aimed at treating moderate to severe acne [1] - The drug was originally developed by Sagimet Biosciences, and Gilead holds exclusive rights for it in Greater China [1] Market Positioning - According to Industrial Securities, Gilead is focusing on the weight loss metabolic field, addressing core pain points with a deep pipeline layout [1] - The company is expected to maintain a differentiated competitive advantage in the weight loss sector, especially with the potential readout of phase II data for small molecule GLP-1R agonists and further progress in the THRβ pipeline [1] - The acne treatment drug ASC40 is anticipated to gradually contribute to the company's revenue [1]

兴业证券此前指出，歌礼制药在减重代谢领域持续投入，聚焦减重赛道核心痛点进行深度管线布局。随 着小分子GLP-1R激动剂二期数据的潜在读出以及THRβ管线的进一步进展，公司在减重领域有望持续展 现差异化竞争优势。公司引进的痤疮治疗药物ASC40也有望逐渐为公司贡献收入。 消息面上，12月4日，CDE 官网显示，歌礼的1类新药地尼法司他片上市申请获得受理。根据该药的临 床研究进度，Insight 数据库推测本次申请的适应症为用于治疗中重度寻常性痤疮。地尼法司他 (Denifanstat，ASC40) 是一款潜在 First-in-class、每日一次口服脂肪酸合成酶 (FASN) 抑制剂。该药最初 由 Sagimet Biosciences 开发，歌礼拥有其在大中华区的独家权益。 智通财经APP获悉，歌礼制药-B(01672)涨超4%，截至发稿，涨4.25%，报14.23港元，成交额2682.71万 港元。 ...

消息面上，12月4日，CDE官网显示，歌礼的1类新药地尼法司他片上市申请获得受理。根据该药的临床 研究进度，Insight数据库推测本次申请的适应症为用于治疗中重度寻常性痤疮。地尼法司他 (Denifanstat，ASC40)是一款潜在First-in-class、每日一次口服脂肪酸合成酶(FASN)抑制剂。该药最初由 Sagimet Biosciences开发，歌礼拥有其在大中华区的独家权益。 歌礼制药-B(01672)涨超4%，截至发稿，涨4.25%，报14.23港元，成交额2682.71万港元。 兴业证券此前指出，歌礼制药在减重代谢领域持续投入，聚焦减重赛道核心痛点进行深度管线布局。随 着小分子GLP-1R激动剂二期数据的潜在读出以及THRβ管线的进一步进展，公司在减重领域有望持续展 现差异化竞争优势。公司引进的痤疮治疗药物ASC40也有望逐渐为公司贡献收入。 ...

歌礼制药-B回购明细 | 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.12.04 | 162.00 | 13.230 | 12.330 | 2093.89 | | 2025.12.03 | 130.60 | 12.480 | 11.680 | 1592.75 | | 2025.11.05 | 10.00 | 9.320 | 9.100 | 92.40 | | 2025.10.31 | 20.00 | 9.730 | 9.370 | 193.27 | | 2025.10.28 | 10.00 | 9.310 | 9.140 | 91.89 | | 2025.10.27 | 10.00 | 9.730 | 9.580 | 97.00 | | 2025.10.23 | 20.00 | 9.200 | 8.860 | 180.30 | | 2025.10.22 | 10.00 | 9.340 | 9.220 | 92.65 | | 2025.10.17 | 10.00 | 9.31 ...

Core Viewpoint - The company, Gilead Sciences-B (01672), announced a share buyback plan, indicating confidence in its financial position and future prospects [1] Group 1 - The company will repurchase 1.62 million shares [1] - The total expenditure for the buyback is HKD 20.9389 million [1] - The buyback price range is set between HKD 12.33 and HKD 13.23 per share [1]

智通财经APP讯，歌礼制药-B(01672)发布公告，于2025年12月4日该公司斥资2093.89万港元回购162万 股，回购价格为每股12.33-13.23港元。 ...

表格類別： 股票 狀態： 新提交 公司名稱： 歌禮製藥有限公司 呈交日期： 2025年12月4日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01672 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下 ...

Core Viewpoint - The innovative drug concept stocks have shown a rebound, with notable increases in share prices for several companies, driven by recent developments in the healthcare policy landscape in China [1]. Group 1: Stock Performance - Gilead Sciences-B (01672) increased by 10.26%, reaching HKD 13.11 [1] - Kangfang Biotech (09926) rose by 4.15%, reaching HKD 123.1 [1] - Zai Lab (09688) saw a 3.36% increase, reaching HKD 15.69 [1] - Xiansheng Pharmaceutical (02096) grew by 2.9%, reaching HKD 13.48 [1] Group 2: Policy Developments - In November, the National Healthcare Security Administration initiated negotiations for the 2025 National Basic Medical Insurance Drug List and the pricing consultation for the commercial insurance innovative drug list [1] - The fourth batch of traditional Chinese medicine centralized procurement was launched nationwide [1] - Beijing introduced policies related to medical devices, and the State Council meeting outlined the promotion of provincial-level coordination for basic medical insurance [1] Group 3: Market Insights - Bohai Securities highlighted the importance of the upcoming release of the new basic medical insurance drug list and the first commercial insurance innovative drug list in early December, indicating potential investment opportunities for related pharmaceutical companies [1] - Zhongyou Securities noted that despite a temporary vacuum in domestic BD (business development) transactions, there have been multiple collaborations with multinational corporations (MNCs) since Q4, reflecting recognition of the innovative research capabilities of domestic companies [1] - The strong competitive advantages of China's innovative drug industry, including the capacity of the industry chain, pipeline quantity and quality, and research efficiency, are expected to foster long-term positive trends [1]

Core Viewpoint - The innovative pharmaceutical stocks have shown a rebound, with notable increases in share prices for several companies, driven by recent policy developments and market dynamics [1] Group 1: Stock Performance - Gilead Sciences-B (01672) increased by 10.26%, reaching HKD 13.11 [1] - Kangfang Biotech (09926) rose by 4.15%, reaching HKD 123.1 [1] - Zai Lab (09688) saw a 3.36% increase, reaching HKD 15.69 [1] - Xiansheng Pharmaceutical (02096) grew by 2.9%, reaching HKD 13.48 [1] Group 2: Policy Developments - In November, the National Healthcare Security Administration initiated negotiations for the 2025 National Basic Medical Insurance Drug List and the pricing consultation for the commercial insurance innovative drug list [1] - The fourth batch of traditional Chinese medicine centralized procurement was launched, and new policies regarding medical devices were introduced in Beijing [1] - The State Council meeting outlined plans to promote provincial-level coordination of basic medical insurance [1] Group 3: Market Insights - Bohai Securities highlighted the importance of the upcoming release of the new basic medical insurance drug list and the first commercial insurance innovative drug list in early December, indicating potential investment opportunities in related pharmaceutical companies [1] - Zhongyou Securities noted that despite a temporary vacuum in domestic BD outbound transactions, several collaborations with multinational corporations (MNCs) have emerged since Q4, reflecting the recognition of domestic innovative drug companies' R&D capabilities [1] - The strong competitive advantages of China's innovative drug industry, including the capacity of the industry chain, pipeline quantity and quality, and R&D efficiency, are expected to drive long-term industry trends [1]